Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 platelet inhibitor.
## Primary Indications
* **Acute Coronary Syndromes (ACS):** In combination with aspirin for the prevention of thrombotic events (e.g., myocardial infarction, stroke) in patients with ACS.
* **History of Myocardial Infarction (MI):** In patients with a history of MI and high risk for occlusive cardiovascular events, in combination with aspirin.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for up to 12 months, or as clinically indicated. In some patients, especially those with a history of MI, therapy may be extended beyond 12 months.
* **History of MI:**
* **Maintenance Dose:** 60 mg orally twice daily.
* **Switching from other P2Y12 inhibitors:** No formal washout period is required.
## Pediatric Dosing
No established pediatric dosing. Ticagrelor is not recommended for use in children.
## Dose Adjustments
No specific dose adjustments are generally required based on renal or hepatic impairment. However, caution is advised in severe hepatic impairment.
## Contraindications
* Hypersensitivity to ticagrelor or any of its components.
* Active pathological bleeding.
## Adverse Effects
* **Most Common:** Bleeding (including fatal and intraocular), dyspnea, bradycardia, ventricular pauses, elevated uric acid, creatinine.
* **Serious:** Major bleeding, life-threatening bleeding, cerebral bleeding.
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors/Inducers:** May increase or decrease ticagrelor exposure, respectively. Avoid co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin). Use with caution with strong CYP3A4 inducers (e.g., rifampin, carbamazepine).
* **P-glycoprotein (P-gp) Inhibitors:** Increased ticagrelor exposure with co-administration of P-gp inhibitors (e.g., cyclosporine).
* **Aspirin:** Combination increases bleeding risk; use judiciously and for the indicated duration.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding.
## Monitoring
* **Bleeding:** Closely monitor for signs and symptoms of bleeding, especially during the first few months of treatment.
* **Renal Function:** Monitor periodically.
* **Hepatic Function:** Monitor periodically, especially in patients with hepatic impairment.
* **Uric Acid:** Monitor periodically.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel.
* Dyspnea is a common side effect and usually does not require discontinuation.
* The 90 mg twice daily dose is indicated for ACS and a history of MI if extended therapy beyond 1 year is considered. The 60 mg twice daily dose is for patients with a history of MI.
* Discontinuation of ticagrelor may increase the risk of thrombotic events. If discontinuation is necessary for surgical reasons, discuss appropriate management of antiplatelet therapy with the treating physician.
---
*This information is intended for healthcare professionals. Always consult the official prescribing information and local guidelines for complete and up-to-date details before making clinical decisions.*
